Sanofi converts Attovia preferred and buys IPO shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sanofi, through wholly owned subsidiaries, converted 782,855 shares of Attovia Therapeutics Series C preferred stock into 782,855 shares of common stock automatically upon Attovia’s IPO on August 6, 2026, and also purchased 300,000 common shares in the IPO at $17.00 per share. Following the IPO, Sanofi stated its beneficial ownership fell below 10% due to additional common shares issued.
Insider Trade Summary
Net Buyer: 300,000 shares
Net Buy
3 txns
Insider
Sanofi
Role
10% Owner
Bought
300,000 shs ($5.10M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series C Preferred Stock F1, F3 | 782,855 | -- | -- |
| Conversion | Common Stock F1, F3 | 782,855 | -- | -- |
| Purchase | Common Stock F2, F3 | 300,000 | $17.00 | $5.10M |
Holdings After Transaction:
Series C Preferred Stock — 0 contracts (Indirect, See footnote);
Common Stock — 1,082,855 shares (Indirect, See footnote)
Footnotes (3)
- F1. The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026.
- F2. Represents a purchase in the Issuer's IPO.
- F3. Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
Key Figures
Preferred shares converted: 782,855 shares
Common shares received from conversion: 782,855 shares
IPO common shares purchased: 300,000 shares
+2 more
5 metrics
Preferred shares converted
782,855 shares
Series C preferred stock automatically converted into common upon Attovia’s IPO on August 6, 2026
Common shares received from conversion
782,855 shares
Common stock received indirectly by Sanofi subsidiaries from Series C preferred conversion
IPO common shares purchased
300,000 shares
Purchase in Attovia’s IPO reported as indirect ownership
IPO purchase price
$17.00 per share
Price paid for 300,000 common shares in Attovia’s initial public offering
Post-IPO ownership threshold
Below 10%
Sanofi’s beneficial ownership of Attovia common stock after additional IPO shares were issued
Key Terms
Series C preferred stock, initial public offering (the "IPO"), beneficially owns, Conversion of derivative security
4 terms
Series C preferred stock financial
"The Series C preferred stock converted by its terms in full automatically"
A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.
initial public offering (the "IPO") financial
"upon the consummation of the Issuer's initial public offering (the "IPO")"
beneficially owns financial
"Sanofi beneficially owns the securities reported herein through various"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
Conversion of derivative security financial
"transaction_code_description": "Conversion of derivative security""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Attovia (ATTO) securities did Sanofi convert in this Form 4?
Sanofi converted 782,855 shares of Attovia Therapeutics Series C preferred stock into 782,855 shares of common stock. The conversion occurred automatically upon Attovia’s IPO on August 6, 2026, eliminating Sanofi’s reported preferred stock position.
Did Sanofi’s ownership in Attovia (ATTO) remain above 10% after the IPO?
No. Sanofi states its beneficial ownership of Attovia common stock fell below 10% immediately upon consummation of the IPO. This change resulted from Attovia issuing additional common shares in the IPO, which reduced Sanofi’s ownership percentage.
How are Sanofi’s Attovia (ATTO) holdings characterized in this Form 4?
Sanofi’s holdings are reported as indirectly owned through various wholly owned subsidiaries. The Form 4 notes that Sanofi beneficially owns the securities via these subsidiaries, clarifying that the positions are not held directly in Sanofi’s own name.
Was Sanofi’s Attovia (ATTO) trading under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as being under such a plan. There is no footnote indicating these transactions were executed pursuant to a pre-arranged trading plan, so they are presented as discretionary activity.
What happened to Sanofi’s Series C preferred stock in Attovia (ATTO)?
The Series C preferred stock converted in full automatically into common stock upon Attovia’s IPO on August 6, 2026. After this automatic conversion, the Form 4 shows 0 shares of Series C preferred stock remaining for the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
